Tiziana Life Sciences (NASDAQ: TLSA) has announced that the first patient has been dosed with intranasal foralumab in its Phase 2 randomized, placebo-controlled clinical trial in patients with early Alzheimer’s disease...
VYNE Therapeutics (NASDAQ: VYNE) has announced that it has entered into a merger agreement with closely held Yarrow Bioscience, with the combined companies expected to operate as Yarrow Bioscience under the ticker...
CERo Therapeutics (OTCQB: CERO) has announced advancements to the CertainT-1 trial focused on patients with acute myeloid leukemia (AML). According to CERo, following completion of the dose-limiting toxicity (DLT)...
Adagene (NASDAQ: ADAG) has announced that the FDA has designated muzastotug, in combination with Merck’s (NYSE: MRK) anti-PD-1 therapy, KEYTRUDA (pembrolizumab), as a fast track product for adult patients with...
PolyPid (NASDAQ: PYPD) has announced the appointment of medtech leader Brooke Story as chair of the board of directors (BOD), effective December 11, 2025. Ms. Story brings more than 25 years of leadership experience in...
Closely held Aqua Medical is advancing therapy for gastrointestinal (GI) and metabolic diseases—including Type 2 diabetes—using its disruptive, transoral, outpatient vapor-based endoscopic ablation platform.
ENvue Medical (NASDAQ: FEED) announced the appointment of David Johnson as chairman of the board. Mr. Johnson is a seasoned healthcare executive and board leader with more than 30 years of experience across the medical...
RedHill Biopharma (NASDAQ: RDHL) has announced positive in vivo results that indicate opaganib combined with venetoclax reduces chronic lymphocytic leukemia (CLL) cells by half compared to controls—demonstrating...
Kyverna Therapeutics (NASDAQ: KYTX) has announced positive topline data from KYSA-8, its registrational Phase 2 trial of mivocabtagene autoleucel (miv-cel)—a fully human, autologous CD19-targeting CAR T-cell therapy...
Cadrenal Therapeutics (NASDAQ: CVKD) has announced the acquisition of VLX-1005—a first-in-class, Phase 2 12-LOX inhibitor—along with additional 12-lipoxygenase (12-LOX) assets from closely held Veralox Therapeutics, for...